A noncoding single-nucleotide polymorphism at 8q24 drives IDH1-mutant glioma formation
Authors
- C. Yanchus
- K.L. Drucker
- T.M. Kollmeyer
- R. Tsai
- W. Winick-Ng
- M. Liang
- A. Malik
- J. Pawling
- S.B. De Lorenzo
- A. Ali
- P.A. Decker
- M.L. Kosel
- A. Panda
- K.N. Al-Zahrani
- L. Jiang
- J.W.L. Browning
- C. Lowden
- M. Geuenich
- J.J. Hernandez
- J.T. Gosio
- M. Ahmed
- S.K. Loganathan
- J. Berman
- D. Trcka
- K.A. Michealraj
- J. Fortin
- B. Carson
- E.W. Hollingsworth
- S. Jacinto
- P. Mazrooei
- L. Zhou
- A. Elia
- M. Lupien
- H.H. He
- D.J. Murphy
- L. Wang
- A. Abyzov
- J.W. Dennis
- P.G. Maass
- K. Campbell
- M.D. Wilson
- D.H. Lachance
- M. Wrensch
- J. Wiencke
- T. Mak
- L.A. Pennacchio
- D.E. Dickel
- A. Visel
- J. Wrana
- M.D. Taylor
- G. Zadeh
- P. Dirks
- J.E. Eckel-Passow
- L. Attisano
- A. Pombo
- C.M. Ida
- E.Z. Kvon
- R.B. Jenkins
- D. Schramek
Journal
- Science
Citation
- Science 378 (6615): 68-78
Abstract
Establishing causal links between inherited polymorphisms and cancer risk is challenging. Here, we focus on the single-nucleotide polymorphism rs55705857, which confers a sixfold greater risk of isocitrate dehydrogenase ((IDH)-mutant low-grade glioma (LGG). We reveal that rs55705857 itself is the causal variant and is associated with molecular pathways that drive LGG. Mechanistically, we show that rs55705857 resides within a brain-specific enhancer, where the risk allele disrupts OCT2/4 binding, allowing increased interaction with the (Myc) promoter and increased (Myc) expression. Mutating the orthologous mouse rs55705857 locus accelerated tumor development in an Idh1(R132H)-driven LGG mouse model from 472 to 172 days and increased penetrance from 30% to 75%. Our work reveals mechanisms of the heritable predisposition to lethal glioma in ~40% of LGG patients.